Advanced search
Publication Cover
Biotechnology & Biotechnological Equipment Volume 29, 2015 - Issue 1
Submit an article Journal homepage
784
Views
10
CrossRef citations to date
0
Altmetric
Article; Medical Biotechnology

Combination of Tripterygium wilfordii Hook F and angiotensin receptor blocker synergistically reduces excretion of urinary podocytes in patients with type 2 diabetic kidney disease

Ruixia MaDepartment of Nephrology, Affiliated Hospital of Medical College, Qingdao University, Qingdao, Shandong, P.R. ChinaCorrespondence[email protected]
View further author information
,
Yan XuDepartment of Nephrology, Affiliated Hospital of Medical College, Qingdao University, Qingdao, Shandong, P.R. ChinaView further author information
,
Wei JiangDepartment of Nephrology, Affiliated Hospital of Medical College, Qingdao University, Qingdao, Shandong, P.R. ChinaView further author information
&
Wei ZhangDepartment of Nephrology, Affiliated Hospital of Medical College, Qingdao University, Qingdao, Shandong, P.R. ChinaView further author information
Pages 139-146 | Received 28 Feb 2014, Accepted 05 Aug 2014, Published online: 11 Dec 2014

References

  • Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes. 2005;54(6):1626–1634.
  • Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev. 2008;4(1):39–45.
  • Jim B, Santos J, Spath F, Cijiang He J. Biomarkers of diabetic nephropathy, the present and the future. Curr Diabetes Rev. 2012;8(5):317–328.
  • Weil EJ, Lemley KV, Yee B, Lovato T, Richardson M, Myers BD, Nelson RG. Podocyte detachment in type 2 diabetic nephropathy. Am J Nephrol. 2011;33(s1):21–24.
  • Sun D, Zhao X, Meng L. Relationship between urinary podocytes and kidney diseases. Ren Fail. 2012;34(3):403–407.
  • Hara M, Yamagata K, Tomino Y, Saito A, Hirayama Y, Ogasawara S, Kurosawa H, Sekine S, Yan K. Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin. Diabetologia. 2012;55(11):2913–2919.
  • Wang G, Lai FM, Lai KB, Chow KM, Kwan BC, Li PK, Szeto CC. Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker. Eur J Endocrinol. 2008;158(3):317–322.
  • Zhang M, Zhu T, Peng A, You L, Zhu W, Chen J, Gu Y, Lin S. Effects of losartan on urinary podocyte excretion in diabetic nephropathy patients. Chin J Nephrol. 2006;22:72–75. Chinese.
  • Ma R, Liu L, Liu X, Wang Y, Jiang W, Xu L. Triptolide markedly attenuates albuminuria and podocyte injury in an animal model of diabetic nephropathy. Exp Ther Med. 2013;6:649–656.
  • Song HX, Gong J, Chen W. Effect of triptolide on urinary monocyte chemottractant protein-1 in patients with diabetic nephropathy. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2005;25:416–418. Chinese.
  • Gao Q, Shen W, Qin W, Zheng C, Zhang M, Zeng C, Wang S, Wang J, Zhu X, Liu Z. Treatment of db/db diabetic mice with triptolide: a novel therapy for diabetic nephropathy. Nephrol Dial Transplant. 2010;25(11):3539–3547.
  • Ma RX, Liu XM, Liu LQ, Li HN. Effects of triptolide on the podocyte protein expression of nephrin and podocin and its mechanism in type 2 diabetic rats. Chin J Diabetes. 2010;2:291–296. Chinese.
  • Ma RX, Xu Y, Zhang J, Li YS, Liu LQ. Triptolide combined with irbesartan synergistically blocks podocyte injury in a type 2 diabetes rat model. Zhonghua Nei Ke Za Zhi. 2012;51:117–122. Chinese.
  • Ma RX, Zhao N, Zhang W. The effects and mechanism of Tripterygium wilfordii Hook F combination with irbesartan on urinary podocyte excretion in diabetic nephropathy patients. Zhonghua Nei Ke Za Zhi. 2013;52:469–473. Chinese.
  • Diez-Sampedro A, Lenz O, Fornoni A. Podocytopathy in diabetes: a metabolic and endocrine disorder. Am J Kidney Dis. 2011;58(4):637–646.
  • Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol. 2007;106(2):26–31.
  • Hiromura K, Haseley LA, Zhang P, Monkawa T, Durvasula R, Petermann AT, Alpers CE, Mundel P, Shankland SJ. Podocyte expression of the CDK-inhibitor p57 during development and disease. Kidney Int. 2001;60(6):2235–2246.
  • Kelly KJ, Dominguez JH. Treatment of the post-ischaemic inflammatory syndrome of diabetic nephropathy. Nephrol Dial Transplant. 2010;25(10):3204–3212.
  • Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, Dorfman R, Wang Y, Zielenski J, Mastronardi F, Maezawa Y, Drucker DJ, Engleman E, Winer D, Dosch HM. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med. 2009;15(8):921–929.
  • Lorenzen J, Shah R, Biser A, Staicu SA, Niranjan T, Garcia AM, Gruenwald A, Thomas DB, Shatat IF, Supe K, Woroniecki RP, Susztak K. The role of osteopontin in the development of albuminuria. J Am Soc Nephrol. 2008;19(5):884–890.
  • Mason RM. Connective tissue growth factor (CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it? J Cell Commun Signal. 2009;3(2):95–104.
  • Takano Y, Yamauchi K, Hayakawa K, Hiramatsu N, Kasai A, Okamura M, Yokouchi M, Shitamura A, Yao J, Kitamura M. Transcriptional suppression of nephrin in podocytes by macrophages: roles of inflammatory cytokines and involvement of the PI3K/Akt pathway. FEBS Lett. 2007;581(3):421–426.
  • Li LS, Liu ZH. Twenty-five years’ experience with Tripterygium for nephritis treatment. J Nephrol Dial Transplant. 2003;12:246–247. Chinese.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.